ARCHIVES

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 17 | May 2, 2008

Download PDF Visit The Full Archive

Related Articles

Cuts From NCI Budget total $38 Million; Prevention Gets $21 Million Increase

January 24, 1992

DCCR Plans Three Multiple Contracts In Pain Control

February 17, 1978

Translplants Not Best Choice in Subset of ALL Patients

April 27, 2012

Treatment research Reports Summarized; New MTX Rescues

May 6, 1977

Professional Societies: ASCO Seeks Balance In Roles As U.S., International Society

May 23, 1997

NCI Cooperative Group, Cancer Center Trials Listed

January 25, 2008